Supplementary material to article by D. Roblin et al. "Topical TrkA Kinase Inhibitor CT327 is an Effective, Novel Therapy for the Treatment of Pruritus due to Psoriasis: Results from In vitro and Tissue Experimental Studies, and Efficacy and Safety of CT327 in a Phase 2b, Randomised, Double-blind, Vehicle-controlled Clinical Trial in Patients with Psoriasis"

Table SI. Study demographics

| | CT327 0.05% | CT327 0.1% | CT327 0.5% | Vehicle |
|--|-----------------|-----------------|-----------------|-----------------|
| Total study population (full analysis set) | n=40 | n=40 | n=40 | n=40 |
| Age, years, mean \pm SD | 48.7 ± 14.4 | 48.3 ± 13.5 | 49.4 ± 15.6 | 50.7 ± 14.4 |
| Male, <i>n</i> (%) | 25 (63) | 26 (65) | 25 (63) | 29 (73) |
| Female, <i>n</i> (%) | 15 (38) | 14 (35) | 15 (38) | 11 (28) |
| Time since diagnosis of psoriasis, years, mean ± SD | 19.1 ± 12.2 | 16.8 ± 13.0 | 17.0 ± 13.1 | 20.0 ± 14.0 |
| Baseline modified Psoriasis Area and Severity Index score, mean ± SD | 8.7 ± 2.7 | 9.0 ± 2.6 | 9.3 ± 2.6 | 8.5 ± 2.4 |
| Baseline pruritus Visual Analogue Scale score (mm), mean ± SD ^a | 51.9 ± 24.6 | 50.6 ± 25.3 | 57.3 ± 22.5 | 43.6 ± 29.8 |
| Subjects with baseline Visual Analogue Scale ≥40 mm (full analysis set) | n=29 | n=26 | n = 31 | n=22 |
| Age, years, mean ± SD | 48.3 ± 14.0 | 45.5 ± 12.8 | 47.5 ± 15.5 | 51.6 ± 14.2 |
| Male, <i>n</i> (%) | 16 (55) | 17 (65) | 23 (74) | 16 (73) |
| Female, <i>n</i> (%) | 13 (45) | 9 (35) | 8 (26) | 6 (27) |
| Time since diagnosis of psoriasis, years, mean ± SD | 17.8 ± 11.4 | 14.2 ± 10.3 | 14.8 ± 10.6 | 18.2 ± 13.2 |
| Baseline modified Psoriasis Area and Severity Index score, mean ± SD | 9.1 ± 2.8 | 9.6 ± 2.1 | 9.5 ± 2.6 | 8.9 ± 2.6 |
| Baseline pruritus Visual Analogue Scale score (mm), mean ± SD | 64.3 ± 14.2 | 64.8 ± 17.0 | 66.3 ± 14.6 | 65.5 ± 18.7 |

^an=39 for CT327 0.1%, CT327 0.5% and vehicle groups.